



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

31 October 2017  
EMA/CAT/837016/2017  
Inspections, Human Medicines Pharmacovigilance and Committees Division

## Committee for Advanced Therapies (CAT)

Minutes for the meeting on 04-06 October 2017

Chair: Martina Schübler-Lenz; Vice-Chair: Ilona Reischl

### Health and safety information

In accordance with the Agency's health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting.

### Disclaimers

Some of the information contained in these minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CAT meeting reports once the procedures are finalised.

Of note, the minutes are a working document primarily designed for CAT members and the work the Committee undertakes.

### Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).



## Table of contents

<b>1.</b>	<b>Introduction</b>	<b>5</b>
1.1.	Welcome and declarations of interest of members, alternates and experts.....	5
1.2.	Adoption of agenda .....	5
1.3.	Adoption of the minutes .....	5
<b>2.</b>	<b>Evaluation of ATMPs</b>	<b>5</b>
2.1.	Opinions .....	5
2.2.	Oral explanations .....	5
2.3.	Day 180 list of outstanding issues .....	5
2.4.	Day 120 list of questions .....	5
2.5.	Day 80 assessment reports .....	6
2.6.	Update on ongoing initial applications.....	6
2.7.	New applications .....	6
2.7.2.	tisagenlecleucel-T - Orphan – H0004090 .....	6
2.8.	Withdrawal of initial marking authorisation application .....	6
2.9.	Re-examination of initial application procedures under Article 9(2) of Regulation No. 726/2004 .....	6
2.10.	GMP and GCP inspections requests.....	6
2.11.	Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008 .....	6
2.11.1.	Zalmoxis - allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor ( $\Delta$ LNNGFR) and the herpes simplex I virus thymidine kinase (HSV-TK Mut2) - Orphan - EMEA/H/C/002801/II/0005/G .....	6
2.11.2.	MACI - matrix applied characterised autologous cultured chondrocytes - EMEA/H/C/002522/II/0014/G .....	7
2.12.	Other Post-Authorisation Activities .....	7
2.12.1.	Holoclar - <i>ex vivo</i> expanded autologous human corneal epithelial cells containing stem cells - Orphan - EMEA/H/C/002450/R/0015.....	7
<b>3.</b>	<b>Certification of ATMPs</b>	<b>7</b>
3.1.	Opinion.....	7
3.2.	Day 60 Evaluation Reports.....	7
3.3.	New Applications .....	7
<b>4.</b>	<b>Scientific Recommendation on Classification of ATMPs</b>	<b>8</b>
4.1.	New requests – Appointment of CAT Coordinator .....	8
4.1.1.	CD1c (BDCA1)+ myeloid dendritic cells (myDC) - H0004927.....	8
4.1.2.	Genetically modified epithelial cells (factor IX), encapsulated – H0004928.....	8
4.1.3.	Stromal vascular fraction (SVF) – H0004926.....	8

<b>4.2.</b>	<b>Day 30 ATMP scientific recommendation</b> .....	<b>8</b>
4.2.1.	Allogenic cardiopoietic cells derived from adipose tissue derived stem cells (ADSC) purified from healthy donor's lipoaspirate – H0004911 .....	8
4.2.2.	Recombinant adeno-associated virus serotype 2/1 vector encoding human $\beta$ -hexosaminidase alpha & beta subunits (rAAV2/1 Hex alpha & beta) – H0004906 .....	9
4.2.3.	Adeno-associated virus (AAV) vector serotype 8 expressing human low-density lipoprotein receptor (hLDLR) - H0004905 .....	9
4.2.4.	Skin tissue – H0004907 .....	9
4.2.5.	Autologous CD34+ cells, freshly isolated – H0004922 .....	9
4.2.6.	Autologous dental pulp stem cells (DPSC), freshly isolated – H0004923 .....	10
4.2.7.	Cultured dental pulp stem cells (DPSC) – H0004924 .....	10
<b>4.3.</b>	<b>Day 60 revised scientific recommendation (following list of questions)</b> .....	<b>10</b>
<b>4.4.</b>	<b>Finalisation of procedure</b> .....	<b>10</b>
4.4.1.	Allogeneic human glial-restricted precursors - H0004887/0001 .....	10
4.4.2.	Allogeneic human glial-restricted precursors - H0004898/0001 .....	10
4.4.3.	Nuclease-resistant, synthetic double-stranded, small interfering ribonucleic acid (siRNA) designed to temporarily inhibit the expression of the collagen-specific chaperone, heat shock protein 47 (HSP47) - H0004900/0001 .....	11
4.4.4.	Messenger RNA encoding immunostimulatory proteins constitutively active Toll-like receptor 4, cluster of differentiation 40 ligand and cluster of differentiation 70 and tumour associated antigens - H0004899/0001 .....	11
4.4.5.	Cultured viable chondrocytes in a 3-dimensional hydrogel - H0004901/0001 .....	11
<b>4.5.</b>	<b>Follow-up and guidance</b> .....	<b>11</b>
<b>5.</b>	<b>Scientific Advice</b> .....	<b>11</b>
5.1.	<b>New requests – appointment of CAT Rapporteurs</b> .....	<b>11</b>
5.2.	<b>CAT reports</b> .....	<b>12</b>
5.3.	<b>List of Issues</b> .....	<b>12</b>
5.4.	<b>Finalisation of SA procedures</b> .....	<b>12</b>
<b>6.</b>	<b>Pre-Authorisation Activities</b> .....	<b>12</b>
6.1.	<b>Paediatric investigation plans</b> .....	<b>12</b>
6.2.	<b>ITF briefing meetings in the field of ATMPs</b> .....	<b>12</b>
6.3.	<b>Priority Medicines (PRIME) – Eligibility requests</b> .....	<b>12</b>
6.3.1.	Month 0 - Start of the procedure .....	12
6.3.2.	Month 1 – Discussion of eligibility .....	12
6.3.3.	Month 2 – Recommendation of eligibility .....	12
6.3.4.	Month 3 – Nomination of Rapporteurs .....	12
6.3.5.	Month 4 – Ongoing support .....	12
<b>7.</b>	<b>Organisational, regulatory and methodological matters</b> .....	<b>12</b>
7.1.	<b>Mandate and organisation of the CAT</b> .....	<b>12</b>
7.1.1.	Strategic Review & Learning meeting – Tallinn, Estonia, 15-17 November 2017 .....	12

<b>7.2.</b>	<b>Coordination with EMA Scientific Committees.....</b>	<b>13</b>
7.2.1.	Committee for Medicinal Products for Human Use (CHMP) .....	13
7.2.2.	Scientific Co-ordination Board (SciCoBo) – meeting on 21 September 2017 .....	13
7.2.3.	Cell based ATMPs-orphan nomenclature .....	13
<b>7.3.</b>	<b>Coordination with EMA Working Parties/Working Groups/Drafting Groups .....</b>	<b>13</b>
7.3.1.	Guideline on quality, non-clinical and clinical aspects of medicinal products containing genetically modified cells.....	13
7.3.2.	Quality support to accelerated access schemes.....	13
7.3.3.	Working Party with Patients’ and Consumers’ Organisations (PCWP) and Working Party with Healthcare Professionals’ Organisations (HCPWP) .....	14
7.3.4.	Review and update of EMA guidelines to implement best practice with regard to 3Rs (replacement, reduction and refinement of animal testing) in regulatory testing of medicinal products.....	14
7.3.5.	CAT representatives in the Scientific Advice Working Party .....	14
<b>7.4.</b>	<b>Cooperation within the EU regulatory network .....</b>	<b>14</b>
7.4.1.	EU Network Pharmacovigilance Oversight Group (EU-POG) (former ERMS FG).....	14
7.4.2.	EU Network training centre (EU-NTC).....	15
<b>7.5.</b>	<b>Cooperation with international regulators .....</b>	<b>15</b>
<b>7.6.</b>	<b>CAT work plan .....</b>	<b>15</b>
7.6.1.	CAT 2018 work plan.....	15
7.6.2.	European Society for Blood and Marrow Transplantation (EBMT)’s support on chimeric antigen receptor T cells (CAR-T) .....	15
7.6.3.	Expert meeting on genome editing, EMA, London, UK, 18 October 2017 .....	16
<b>7.7.</b>	<b>Planning and reporting .....</b>	<b>16</b>
7.7.1.	Planning estimates of forthcoming ATMP MAAs .....	16
<b>7.8.</b>	<b>Others .....</b>	<b>16</b>
<b>8.</b>	<b>Any other business</b>	<b>16</b>
<b>9.</b>	<b>Explanatory notes</b>	<b>17</b>
<b>10.</b>	<b>List of participants</b>	<b>21</b>

## **1. Introduction**

### **1.1. Welcome and declarations of interest of members, alternates and experts**

In accordance with the Agency's policy on handling of declarations of interests of scientific committees' members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the current meeting, the Committee Secretariat announced that no restriction in the involvement of meeting participants in upcoming discussions was identified.

Participants in this meeting were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure and as included in the list of participants. All decisions taken at this meeting were made in the presence of a quorum of members (i.e. 22 or more members were present in the room). All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

### **1.2. Adoption of agenda**

The CAT agenda for the 04-06 October 2017 meeting was adopted.

### **1.3. Adoption of the minutes**

The CAT minutes for the 06-08 September 2017 meeting were adopted.

## **2. Evaluation of ATMPs**

### **2.1. Opinions**

No items

### **2.2. Oral explanations**

No items

### **2.3. Day 180 list of outstanding issues**

No items

### **2.4. Day 120 list of questions**

No items

## 2.5. Day 80 assessment reports

No items

## 2.6. Update on ongoing initial applications

No items

## 2.7. New applications

### 2.7.1. Tisagenlecleucel-T - Orphan – H0004090

---

Novartis Europharm Ltd.; Indicated for:

- the treatment of paediatric and young adult patients 3 to 25 years of age with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL).
- the treatment of adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL)

Scope: Briefing note and the Rapporteurs' recommendation on the request for accelerated assessment.

**Action:** for adoption of timetable

CAT adopted the timetable.

## 2.8. Withdrawal of initial marking authorisation application

No items

## 2.9. Re-examination of initial application procedures under Article 9(2) of Regulation No. 726/2004

No items

## 2.10. GMP and GCP inspections requests

## 2.11. Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

### 2.11.1. Zalmoxis - Allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor ( $\Delta$ LNNGFR) and the herpes simplex I virus thymidine kinase (HSV-TK Mut2) - Orphan - EMEA/H/C/002801/II/0005/G

---

MolMed SpA

Rapporteur: Hans Ovelgönne; CHMP Coordinator: Paula Boudewina Van Hennik

Scope: Quality: RSI

**Action:** for adoption

The Rapporteur presented the outcome of the assessment. CAT adopted the RSI.

### 2.11.2. MACI - Matrix applied characterised autologous cultured chondrocytes - EMEA/H/C/002522/II/0014/G

---

Vericel Denmark ApS

Rapporteur: Christiane Niederlaender; CHMP Coordinator: Greg Markey

Scope: Quality

**Action:** timetable for adoption

CAT adopted the review timetable.

## 2.12. Other Post-Authorisation Activities

Annex C - Post-Authorisation Measures (PAMs): Line listing of ATMPs post authorisation measures with procedures starting in October 2017 will be tabled in CAT MMD two weeks after the current CAT meeting

Annex D - Post-Authorisation Measures (PAMs): Line listing of ATMPs post authorisation measures with procedures concluded in October 2017 will be tabled in CAT MMD two weeks after the current CAT meeting

### 2.12.1. Holoclar - *Ex vivo* expanded autologous human corneal epithelial cells containing stem cells - Orphan - EMEA/H/C/002450/R/0015

---

Chiesi Farmaceutici S.p.A.

Rapporteur: Egbert Flory; CHMP Coordinator: Jan Mueller-Berghaus; PRAC Rapporteur: Julie Williams

Scope: 3<sup>rd</sup> annual reassessment for renewal of marketing authorisation. Opinion

**Action:** for adoption

CAT adopted the third annual reassessment for the renewal of the marketing authorisation of Holoclar.

## 3. Certification of ATMPs

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

### 3.1. Opinion

No items

### 3.2. Day 60 Evaluation Reports

No items

### 3.3. New Applications

No items

## 4. Scientific Recommendation on Classification of ATMPs

### 4.1. New requests – Appointment of CAT Coordinator

#### 4.1.1. CD1c (BDCA1)+ myeloid dendritic cells (myDC) - H0004927

---

Intended for the treatment of patients with advanced, pretreated solid tumours with injectable metastases

Scope: appointment of CAT Coordinator and adoption of timetable

**Action:** for adoption

Nominations were received. The CAT member was appointed as CAT coordinator

#### 4.1.2. Genetically modified epithelial cells (factor IX), encapsulated – H0004928

---

Intended for the treatment of haemophilia B

Scope: appointment of CAT Coordinator and adoption of timetable

**Action:** for adoption

Nominations were received. The CAT member was appointed as CAT coordinator.

#### 4.1.3. Stromal vascular fraction (SVF) – H0004926

---

Intended for the treatment to diminish cancer-related lymphedema in breast cancer patients

Scope: appointment of CAT Coordinator and adoption of timetable

**Action:** for adoption

Nominations were received. The CAT member was appointed as CAT coordinator.

### 4.2. Day 30 ATMP scientific recommendation

#### 4.2.1. Allogenic cardiopoietic cells derived from adipose tissue derived stem cells (ADSC) purified from healthy donor's lipoaspirate – H0004911

---

Intended to help post-myocardial infarction patients in restoring cardiac function by targeting for repair the underlying myocardium damage

Scope: scientific recommendation

**Action:** for adoption

CAT discussed the ATMP classification report. CAT adopted the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 20 October 2017.

The CAT recommendation will be considered final if no comments are received from the European Commission. The final report will be sent thereafter to the applicant.



#### 4.2.2. Recombinant adeno-associated virus serotype 2/1 vector encoding human $\beta$ -hexosaminidase alpha & beta subunits (rAAV2/1 Hex alpha & beta) – H0004906

---

Intended for the treatment of Tay-Sachs disease & Sandhoff disease monosialic ganglioside 2 (GM2) gangliosidosis

Scope: scientific recommendation

**Action:** for adoption

CAT discussed the ATMP classification report. CAT adopted the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 20 October 2017.

The CAT recommendation will be considered final if no comments are received from the European Commission. The final report will be sent thereafter to the applicant.

#### 4.2.3. Adeno-associated virus (AAV) vector serotype 8 expressing human low-density lipoprotein receptor (hLDLR) - H0004905

---

Intended for the treatment of hypercholesterolaemia caused by homozygous mutations in the low density lipoprotein receptor (LDLR) gene

Scope: scientific recommendation

**Action:** for adoption

CAT discussed the ATMP classification report. CAT adopted the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 20 October 2017.

The CAT recommendation will be considered final if no comments are received from the European Commission. The final report will be sent thereafter to the applicant.

#### 4.2.4. Skin tissue – H0004907

---

Intended for the treatment of patients with acute complex skin loss

Scope: scientific recommendation

**Action:** for adoption

CAT discussed the ATMP classification report. CAT adopted the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 20 October 2017.

The CAT recommendation will be considered final if no comments are received from the European Commission. The final report will be sent thereafter to the applicant.

#### 4.2.5. Autologous CD34+ cells, freshly isolated – H0004922

---

Cells to be used to contribute the regeneration of soft and hard tissues of temporomandibular joints through their immunological action

Scope: scientific recommendation

**Action:** for adoption

CAT discussed the ATMP classification report. CAT adopted the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 20 October 2017.

The CAT recommendation will be considered final if no comments are received from the European Commission. The final report will be sent thereafter to the applicant.

#### 4.2.6. Autologous dental pulp stem cells (DPSC), freshly isolated – H0004923

---

Intended for the regeneration of soft and hard tissues of temporomandibular joints

Scope: scientific recommendation

**Action:** for adoption

CAT discussed the ATMP classification report. CAT adopted the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 20 October 2017.

The CAT recommendation will be considered final if no comments are received from the European Commission. The final report will be sent thereafter to the applicant.

#### 4.2.7. Cultured dental pulp stem cells (DPSC) – H0004924

---

Intended for the regeneration of soft and hard tissues of temporomandibular joints

Scope: scientific recommendation

**Action:** for adoption

CAT discussed the ATMP classification report. CAT adopted the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 20 October 2017.

The CAT recommendation will be considered final if no comments are received from the European Commission. The final report will be sent thereafter to the applicant.

### 4.3. Day 60 revised scientific recommendation (following list of questions)

No items

### 4.4. Finalisation of procedure

#### 4.4.1. Allogeneic human glial-restricted precursors - H0004887/0001

---

Intended for the treatment of amyotrophic lateral sclerosis

Scope: no comments raised by the European Commission. Final ATMP scientific recommendation

**Action:** for information

The information was noted.

#### 4.4.2. Allogeneic human glial-restricted precursors - H0004898/0001

---

Intended for the treatment of spinal cord injuries

Scope: no comments raised by the European Commission. Final ATMP scientific recommendation

**Action:** for information

The information was noted.

#### 4.4.3. Nuclease-resistant, synthetic double-stranded, small interfering ribonucleic acid (siRNA) designed to temporarily inhibit the expression of the collagen-specific chaperone, heat shock protein 47 (HSP47) - H0004900/0001

---

Intended for the treatment of hepatic fibrosis

Scope: no comments raised by the European Commission. Final ATMP scientific recommendation

**Action:** for information

The information was noted.

#### 4.4.4. Messenger RNA encoding immunostimulatory proteins constitutively active Toll-like receptor 4, cluster of differentiation 40 ligand and cluster of differentiation 70 and tumour associated antigens - H0004899/0001

---

Intended for the treatment of melanoma

Scope: no comments raised by the European Commission. Final ATMP scientific recommendation

**Action:** for information

The information was noted.

#### 4.4.5. Cultured viable chondrocytes in a 3-dimensional hydrogel - H0004901/0001

---

Intended for the treatment of articular cartilage defect of the knee

Scope: no comments raised by the European Commission. Final ATMP scientific recommendation

**Action:** for information

The information was noted.

### 4.5. Follow-up and guidance

No items

## 5. Scientific Advice

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

### 5.1. New requests – appointment of CAT Rapporteurs

Timetable:

-Final Briefing Package:	20.10.2017
-Start of the procedure at SAWP:	23-26.10.2017
-CAT report due by:	26.10.2017
-CAT recommendation:	31.01.2018

## 5.2. CAT reports

## 5.3. List of Issues

No items

## 5.4. Finalisation of SA procedures

# 6. Pre-Authorisation Activities

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

## 6.1. Paediatric investigation plans

## 6.2. ITF briefing meetings in the field of ATMPs

## 6.3. Priority Medicines (PRIME) – Eligibility requests

### 6.3.1. Month 0 - Start of the procedure

### 6.3.2. Month 1 – Discussion of eligibility

### 6.3.3. Month 2 – Recommendation of eligibility

No items

### 6.3.4. Month 3 – Nomination of Rapporteurs

No items

### 6.3.5. Month 4 – Ongoing support

# 7. Organisational, regulatory and methodological matters

## 7.1. Mandate and organisation of the CAT

### 7.1.1. Strategic Review & Learning meeting – Tallinn, Estonia, 15-17 November 2017

CAT Strategic Review & Learning meeting (SRLM) will take place in Tallinn, Estonia on 15-17 November 2017 under the auspices of the Estonian Presidency of the Council of the European Union

Scope: draft programme

**Action:** for discussion

CAT discussed the draft programme, which was agreed with a couple of amendments.

## 7.2. Coordination with EMA Scientific Committees

### 7.2.1. Committee for Medicinal Products for Human Use (CHMP)

---

Scope: Summary of Outcomes (SoO) for the 11–14 September 2017 meeting

**Action:** for information

The information was noted.

### 7.2.2. Scientific Co-ordination Board (SciCoBo) – meeting on 21 September 2017

---

CAT: Martina Schübler-Lenz

Scope: feedback on the outcome of the SciCoBo meeting that took place in September 2017

**Action:** for information

The topic was postponed until the November CAT meeting.

### 7.2.3. Cell based ATMPs-orphan nomenclature

---

Scope: guidance on the terminology for cell-based medicinal products **Action:** for information

The topic was postponed until the November CAT meeting.

## 7.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

### 7.3.1. Guideline on quality, non-clinical and clinical aspects of medicinal products containing genetically modified cells

---

CAT Rapporteur: Marcos Timón

Scope: feedback on the drafting group meeting that took place on 21 September 2017

**Action:** for information

Drafting group: Marcos Timón, Ilona Reischl, Christiane Niederlaender, Belaid Sekkali, Tiina Palomäki, Guido Pantè, Matthias Renner, Marcel Hoefnagel, Brigitte Anliker, Olli Tenhunen, Paolo Gasparini, Martina Schübler-Lenz

A short feedback was given from the drafting group meeting of 21 September 2017 and the planned next steps.

### 7.3.2. Quality support to accelerated access schemes

---

Scope: initiative to support quality aspects on PRIME

**Action:** for endorsement

A presentation was given on the EMA initiative to provide quality input during early development interactions with applicants (e.g. during PRIME kick-off meetings). CAT experts/

members will be asked to contribute: an expression of interest will be launched once CHMP and CAT endorse this initiative.

The CAT chair proposed to have some further internal reflection before appointing a CAT member to this group. This topic will be included in the agenda of a future CAT meeting.

### 7.3.3. Working Party with Patients' and Consumers' Organisations (PCWP) and Working Party with Healthcare Professionals' Organisations (HCPWP)

---

Scope: minutes of PCWP/HCPWP joint meeting that took place on 27-28 June 2017

**Action:** for information

The information was noted.

### 7.3.4. Review and update of EMA guidelines to implement best practice with regard to 3Rs (replacement, reduction and refinement of animal testing) in regulatory testing of medicinal products

---

Scope:

- review of EMA Guidelines considering 3Rs - report on actions taken
- overview of comments received - JEG 3Rs - best practise

**Action:** for comments by 10 November 2017

Note: CAT adopted in September 2016 the comments to the ATMP related entries in the tables included in the reflection paper and agreed on the proposed amendments.

The report and overview of comments documents will be submitted to the CHMP and CVMP in December 2017/January 2018 for adoption and publication. CAT will endorse the documents at its December 2017 CAT meeting.

The topic was postponed until the November 2017 CAT meeting.

### 7.3.5. CAT representatives in the Scientific Advice Working Party

---

Scope: Re-examination of the SAWP composition - call for interest to become one of the CAT representatives in the SAWP.

**Action:** expression of interest to be sent to CAT secretariat by 23 October 2017

EMA presented the proposal for the appointment of 3 CAT members as joint CAT-SAWP members. The role and responsibilities of these joint members was discussed: they will act as liaisons between CAT and the SAWP and act as SAWP coordinators for (a limited number) of scientific advice procedures.

It was agreed to follow-up with an e-mail to all CAT members providing some further clarifications and information. CAT members are asked to express their interest by 23 October 2017.

## 7.4. Cooperation within the EU regulatory network

### 7.4.1. EU Network Pharmacovigilance Oversight Group (EU-POG) (former ERMS FG)

---

Scope: contribution of a CAT representative to the EU-POG

**Action:** for discussion

Note:

-Overview: the EU-POG (formerly known as the European Risk Management Strategy Facilitation Group) was established as a permanent Working Group in 2005. The group aim is to develop a European Strategy for risk management, built on the National Competent Authorities (NCA's) resources and expertise, and incorporating the EMA's role in the coordination and the supervision of products authorised through the EU

-Mandate: *'To prioritise issues for HMA and EMA Management Board consideration, on criteria based on public health and risk to operation of the EU network pharmacovigilance system'*.

-Meeting cycle: bi-monthly by teleconference or face to face meetings when needed.

<http://www.hma.eu/ermsfg.html>

CAT asked EMA to provide some further information on the work load implication of this activity. It was agreed to provide these clarifications and information to all CAT members via e-mail and indicate the deadline for expression of interest.

#### 7.4.2. EU Network training centre (EU-NTC)

---

CAT: Ilona Reishl

Scope: presentation on the work and programme of the EU-NTC

**Action:** for information

A presentation was given to CAT on the EU-NTC and the development of training curricula.

There was a subsequent discussion on the ATMP training curriculum. CAT members were asked to provide input (via e-mail) on (1) what training they consider necessary / helpful for themselves as CAT members and (2) what training would be necessary for the assessors of ATMP clinical trial and marketing authorisation applications. CAT members were asked to indicate the level of the training (beginner, competent, advanced) to their training proposals. Deadline for input by CAT members: 23 October 2017. This feedback will be helpful to guide the discussion on the ATMP curriculum during the SRLM in Tallinn (see 7.1.1). It will also allow the CAT to identify 5 to 7 topics that can be taken forward to develop training sessions.

### 7.5. Cooperation with international regulators

None

### 7.6. CAT work plan

#### 7.6.1. CAT 2018 work plan

---

CAT: Martina Schübler-Lenz

Scope: proposals for the CAT work plan 2018

**Action:** for discussion

The first draft of the 2018 CAT work plan was presented and discussed. Amendments were proposed by CAT, which will be implemented. The revised CAT work plan will be brought to the November CAT meeting for final discussion and adoption.

#### 7.6.2. European Society for Blood and Marrow Transplantation (EBMT)'s support on chimeric antigen receptor T cells (CAR-T)

---

CAT: Martina Schübler-Lenz

Scope: feedback from discussions at the Scientific Coordination Board (SciCoBo) September 2017 meeting

**Action:** for discussion

A short feedback was given from the discussion in the SciCoBo and subsequent discussions with EMA (SAWP secretariat and colleagues responsible for registries). Further feedback and discussion will be provided at the November CAT meeting.

### 7.6.3. Expert meeting on genome editing, EMA, London, UK, 18 October 2017

---

CAT: Paolo Gasparini

Scope: updated agenda

**Action:** for information

The updated agenda was noted. CAT members that are not attending the meeting in person can join via Adobe Connect: the log-in details will be sent in the week starting on 9 October 2017.

## 7.7. Planning and reporting

### 7.7.1. Planning estimates of forthcoming ATMP MAAs

---

Scope: Q3/2017 update of the business pipeline report for the human scientific committees

**Action:** for information

The information was noted.

## 7.8. Others

# 8. Any other business

---

No items

Date of next CAT meeting:

30-31 October 2017 (November 2017 meeting)



## 9. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

### Abbreviations / Acronyms

AR: Assessment Report

ATMP: Advanced Therapy Medicinal Product

BR: Benefit risk

BWP: Biologics Working Party

CAT: Committee for Advanced Therapies

CHMP: Committee for Medicinal Product for Human Use

COMP: Committee for Orphan Medicinal Products

CTFG: Clinical Trial Facilitation Group

DG: Drafting Group

EC: European Commission

ERA: Environmental Risk Assessment

FDA: Food and Drug Administration

FL: Final Letter

GCP: Good Clinical Practice

GLP: Good Laboratory Practice

GMO: Genetically-modified organism

GMP: Good Manufacturing Practice

HTA: Health Technology Assessment Bodies

HSPC: Hematopoietic Stem and Progenitor Cells

ITF: Innovative Task Force

JR: Joint Report

LoOI: List of outstanding issues

LoQ: List of questions

MA: Marketing Authorisation

MAA: Marketing Authorisation Applicant

MAH: Marketing Authorisation Holder

MSC: Mesenchymal stem cells

PDCO: Paediatric Committee

PMDA: Pharmaceuticals and Medical Devices Agency (Japan)

PIP: Paediatric Investigation Plan

PL: Package leaflet

PRAC: Pharmacovigilance and Risk Assessment Committee #

PRIME: Priority Medicines

RMP: Risk Management Plan

RP: Reflection paper

RSI: Request for supplementary information

SA: Scientific Advice  
 SAG-O: Scientific Advisory Group Oncology  
 SAWP: Scientific Advice Working Party  
 SR: Summary Report  
 SWP: Scientific Working Party  
 SME: Small and medium size enterprises  
 SmPC: Summary of Products Characteristics  
 TT: Timetable


## Evaluation of ATMPs (section 2)

This section lists applications for marketing authorisations of new Advanced Therapy Medicinal Products (ATMPs) that are to be discussed by the Committee. It also lists any ATMP related inspection requests (section 2.9) and Post-authorisation activities (section 2.10).

### *New applications (sections 2.1. to 2.12.)*

Section 2.1 is for ATMPs nearing the end of the evaluation and for which the CAT is expected to adopt a draft **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CAT opinion is transmitted to the CHMP for final adoption. The CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU. More information on the evaluation of ATMPs can be found [here](#).

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CAT. The clock stop happens after day 120 and may also happen after day 180, when the CAT has adopted respectively a **Day 120 list of questions** (section 2.3) or a List of outstanding issues to be addressed by the company, which is listed in the agenda under sections 2.7 (**Ongoing evaluation procedures**). Section 2.7 also includes the CAT discussions at any other timepoint of the evaluation procedure of new applications.

### *Oral explanation (section 2.2.)*

Prior to adoption of the CAT opinion, marketing authorisation applicants are normally invited to the CAT plenary meeting to address questions raised by the Committee.

Oral explanations normally relate to ongoing applications, but they can also relate to any other issue for which the CAT would like to discuss with company representatives in person.

### *Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 (section 2.6.)*

This section lists applications for new marketing authorisation for ATMPs for which the applicant has requested a re-examination of the opinion previously issued by the CHMP. Similar to the initial

evaluation of a marketing authorisation of an ATMP, CAT will adopt a draft re-examination opinion, which is transmitted to the CHMP for final adoption.

#### *Withdrawal of applications (section 2.7.)*

This section includes information on marketing authorisation applications that are withdrawn by the applicant. Applicants may decide to withdraw applications at any stage during the assessment and a CAT opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

#### *New applications (section 2.9.)*

In this section, information is included on upcoming marketing authorisation applications for ATMPs, as well as information on appointment of Rapporteurs for new ATMP applications.

#### *GMP and GCP Inspections Issues (section 2.10.)*

This section lists inspections that are undertaken for ATMPs. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

#### *Post-authorisation activities (section 2.12.)*

This section lists type II variations, extension application according to Annex I of Reg. 1234/2008, re-examination procedures for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP and other issues concerning authorised medicines that are not covered elsewhere in the agenda such as annual reassessments, 5-year renewals, supply shortages, qualify defects. Issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines, will also be included here.

### **Certification of ATMPs (section 3)**

This section includes the scientific evaluation by the CAT of quality and non-clinical data that small and medium-sized enterprises have generated at any stage of the ATMP development process. More information on the ATMP certification procedure can be found [here](#).

### **Scientific Recommendation on Classification of ATMPs (Section 4)**

This section includes the scientific recommendation by the CAT on whether medicines based on genes, cells or tissues meet the scientific criteria that define ATMPs. More information on the ATMP classification procedure, including the outcomes of finalised classifications, can be found [here](#).

### **Scientific Advice (section 5)**

This section includes all scientific advice given to companies during the development of an ATMP. Information related to the number of ATMP related scientific advices discussed by CAT can be found in the CAT Monthly reports. Further information on SAWP can be found [here](#).

### **Pre-Authorisation (section 6)**

#### *Paediatric Investigation Plan (PIP)*

This section includes the discussion of an ATMP before a formal application for marketing authorisation is submitted. These cases refer for example to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation: in case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

CAT contributes to the evaluation of a Paediatric Investigation Plan (PIPs) for ATMPs by the Paediatric

Committee. These PIPs are included in this section of the Agenda.

#### *ITF Briefing meeting in the field of ATMPs*

This section refers to briefing meetings of the Innovation Task Force and International co-operations activities of the CAT

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes of meetings with applicants developing ATMPs and of other ITF meetings of interest to the CAT are included in this section of the agenda. Further information on the ITF can be found [here](#).

#### *Priority Medicines (PRIME)*

This section includes the new requests for eligibility to PRIME for ATMPs under development, the discussions in CAT of these eligibility requests and the final recommendations for eligibility of ATMPs adopted by CHMP.

CAT will appoint one of its members as the CAT sponsor for each new ATMP eligibility request who will lead the CAT discussion based on the recommendation from the SAWP.

#### **Organisational, regulatory and methodological matters (section 7)**

This section includes topics related to regulatory and procedural guidance, CAT workplan, CAT meeting organisation (including CAT membership), planning and reporting, co-ordination with other committees, working parties and scientific advisory groups.

Furthermore, this section refers to the activities of the CAT drafting groups developing scientific guidelines for gene therapy medicinal products and for cell-based medicinal products, cooperation within the EU regulatory network and international regulators as well as direct interaction with interested parties. It also includes topics of scientific interest for the Committee that are not directly related to the work of the CAT drafting groups or CAT associated working parties.

#### **Any other business (section 8)**

This section is populated with miscellaneous topics not suitable under the previous headings.

More detailed information on the above terms can be found on the EMA website: [www.ema.europa.eu/](http://www.ema.europa.eu/)

## 10. List of participants

including any restrictions with respect to involvement of members / alternates / experts following evaluation of declared interests for the 04-06 October 2017 meeting.

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Martina Schüssler-Lenz	Chair	Germany	No interests declared	N/A
Ilona Reischl	Member	Austria	No interests declared	N/A
Corina Spreitzer	Alternate	Austria	No interests declared	N/A
Claire Beuneu	Member	Belgium	No interests declared	N/A
Belaïd Sekkali	Alternate	Belgium	No interests declared	N/A
Rozalina Kulaksazova	Member	Bulgaria	No interests declared	N/A
Ivica Malnar	Alternate	Croatia	No interests declared	N/A
Marina Ieridi	Member	Cyprus	No interests declared	N/A
Ivana Haunerová	Member	Czech Republic	No interests declared	N/A
Tomáš Boráň	Alternate	Czech Republic	No interests declared	N/A
Anne Pastoft	Alternate	Denmark	No interests declared	N/A
Toivo Maimets	Member	Estonia	No interests declared	N/A
Olli Tenhunen	Alternate	Finland	No interests declared	N/A
Violaine Closson	Member	France	No interests declared	N/A
Jan Mueller-Berghaus	Member	Germany	No interests declared	N/A
Egbert Flory	Alternate	Germany	No interests declared	N/A
Angeliki Roboti	Alternate	Greece	No interests declared	N/A
Krisztian Fodor	Member	Hungary	No interests declared	N/A
Maura O'Donovan	Member	Ireland	No interests declared	N/A
Paolo Gasparini	Member	Italy	No interests declared	N/A
Una Riekstina	Member	Latvia	No interests declared	N/A
Aija Linē	Alternate	Latvia	No interests declared	N/A
Romaldas Mačiulaitis	Member (CHMP member)	Lithuania	No restrictions applicable to this meeting	N/A
Guy Berchem	Alternate (to CHMP representative)	Luxembourg	No restrictions applicable to this meeting	N/A
Johannes Hendrikus Ovelgönne	Member	Netherlands	No interests declared	N/A
Helga Helga Haugom Olsen	Member	Norway	No interests declared	N/A
Rune Kjekken	Alternate	Norway	No restrictions applicable to this meeting	N/A
Dariusz Śladowski	Member	Poland	No restrictions applicable to this meeting	N/A

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Margarida Menezes-Ferreira	Alternate (to CHMP representative)	Portugal	No interests declared	N/A
Simona Badoi	Member	Romania	No interests declared	N/A
Gianina-Nicoleta Andrei	Alternate	Romania	No interests declared	N/A
Mikuláš Hrubíško	Member	Slovakia	No interests declared	N/A
Ján Kyselovič	Alternate	Slovakia	No interests declared	N/A
Metoda Lipnik-Stangelj	Member	Slovenia	No interests declared	N/A
Marcos Timón	Alternate, replacing CHMP member	Spain	No interests declared	N/A
Lennart Åkerblom	Member	Sweden	No interests declared	N/A
Björn Carlsson	Alternate	Sweden	No interests declared	N/A
Christiane Niederlaender	Member	United Kingdom	No interests declared	N/A
James McBlane	Alternate	United Kingdom	No interests declared	N/A
Mariëtte Driessens	Member	Patients' Representative	No restrictions applicable to this meeting	N/A
Erik Briers	Alternate	Patients' Representative	No restrictions applicable to this meeting	N/A
Kieran Breen	Member	Patients' Representative	No restrictions applicable to this meeting	N/A
Michelino Lipucci di Paola	Alternate	Patients' Representative	No restrictions applicable to this meeting	N/A
Marc Turner	Member	Healthcare Professionals' Representative	No restrictions applicable to this meeting	N/A
Guido Pantè	Expert *	Italy	No interests declared	N/A
Christos Sotirelis	Expert *	Patients' Representative	No interests declared	N/A

A representative from the European Commission attended the meeting

Meeting run with support from relevant EMA staff

\* Experts were only evaluated against the agenda topics or activities they participated in.